Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GDSH is a non-specific acronym used in biomedical research to describe several distinct experimental drug delivery and biomaterial platforms. One prominent application is a **gelatin/starch hydrogel** used as a multifunctional tissue adhesive for advanced wound healing; this version often incorporates antioxidant and antibacterial agents to promote angiogenesis and collagen deposition while regulating M1 macrophage polarization. A second application is a **glucose-responsive dual-drug-sequential delivery hydrogel** composed of oxidized hyaluronic acid and carboxymethyl chitosan, designed for the treatment of chronic tendinopathy in diabetic patients by providing spatiotemporal control over the release of growth factors. A third application involves a **self-assembled nanostructure** composed of gadolinium ions, sodium dodecyl sulfate (SDS), and HEPES, which serves as a platform for stabilizing and delivering hydrophobic molecules. Additionally, the acronym is used in environmental science to refer to a statistical modeling framework (Geodetector-Stepwise-Hierarchical Bayesian).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GDSH.